These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1906375)

  • 1. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.
    Botti RE; Triscari J; Pan HY; Zayat J
    Clin Neuropharmacol; 1991 Jun; 14(3):256-61. PubMed ID: 1906375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.
    Pan HY; Triscari J; DeVault AR; Smith SA; Wang-Iverson D; Swanson BN; Willard DA
    Br J Clin Pharmacol; 1991 Jun; 31(6):665-70. PubMed ID: 1907839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.
    Pan HY; DeVault AR; Wang-Iverson D; Ivashkiv E; Swanson BN; Sugerman AA
    J Clin Pharmacol; 1990 Dec; 30(12):1128-35. PubMed ID: 2125605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.
    Germershausen JI; Hunt VM; Bostedor RG; Bailey PJ; Karkas JD; Alberts AW
    Biochem Biophys Res Commun; 1989 Feb; 158(3):667-75. PubMed ID: 2493245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.
    Pan HY
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S15-8. PubMed ID: 1904355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
    Bocan TM; Ferguson E; McNally W; Uhlendorf PD; Bak Mueller S; Dehart P; Sliskovic DR; Roth BD; Krause BR; Newton RS
    Biochim Biophys Acta; 1992 Jan; 1123(2):133-44. PubMed ID: 1739744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pravastatin and lovastatin in cerebrospinal fluid.
    Triscari J; Markowitz JS; McGovern MW
    Clin Neuropharmacol; 1993 Dec; 16(6):559-60. PubMed ID: 9377592
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
    Chen C; Lin J; Smolarek T; Tremaine L
    Drug Metab Dispos; 2007 Oct; 35(10):1725-9. PubMed ID: 17640956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of diltiazem with lovastatin and pravastatin.
    Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
    Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
    Aronson JK; Ng LL
    Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916
    [No Abstract]   [Full Text] [Related]  

  • 12. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
    Lilja JJ; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.
    Kostis JB; Rosen RC; Wilson AC
    J Clin Pharmacol; 1994 Oct; 34(10):989-96. PubMed ID: 7836550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
    Saheki A; Terasaki T; Tamai I; Tsuji A
    Pharm Res; 1994 Feb; 11(2):305-11. PubMed ID: 8165193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Islam F; Watanabe Y; Hayaishi O
    Biochem Int; 1990 Nov; 22(4):601-5. PubMed ID: 2127671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of new drugs for lowering plasma cholesterol concentrations.
    Illingworth DR
    Drugs; 1991 Feb; 41(2):151-60. PubMed ID: 1709846
    [No Abstract]   [Full Text] [Related]  

  • 19. Pravastatin and simvastatin for hypercholesterolemia.
    Med Lett Drugs Ther; 1991 Mar; 33(839):18-20. PubMed ID: 1899899
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
    Pan HY; DeVault AR; Swites BJ; Whigan D; Ivashkiv E; Willard DA; Brescia D
    Clin Pharmacol Ther; 1990 Aug; 48(2):201-7. PubMed ID: 2116260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.